(Reuters) - Israel-based VBL Therapeutics said a mid-stage study of its experimental brain cancer drug met the main goal of increasing overall survival.
The drug developer's shares were up 20 percent at $6.70 in premarket trade on Wednesday.
19:34 CEO shift at Coca-Cola could usher in more dealmaking to refresh soda giant's growth12
16:52 Synergy Pharma's irritable bowel drug succeeds in key study11
19:30 Virgin Galactic spaceship makes first glide flight48
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff19